Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 11/20 | 0.52 |
| ▸ | CDK1 | P06493 | 7/20 | 0.52 |
| ▸ | CDK9 | P50750 | 6/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.47 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.47 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 7/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.45 |
| ▸ | CCND1 | P24385 | 7/20 | 0.45 |
| ▸ | CCND3 | P30281 | 6/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.45 |
| ▸ | CDK3 | Q00526 | 5/20 | 0.45 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.45 |
| ▸ | PRKDC | P78527 | 2/20 | 0.45 |
| ▸ | CDK7 | P50613 | 4/20 | 0.44 |
| ▸ | STK4 | Q13043 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781003 | 0.88 | CDK2 (0.56) | CDK2CDK1CDK9CCNE1PLK1 | |
| SCHEMBL1781846 | 0.83 | PRKDC (0.62) | CDK2CDK1CDK9CCNE1PLK1 | |
| SCHEMBL29507780 | 0.76 | CDK2 (0.68) | CDK2CDK1CDK9CCNE1CCNE2 | |
| SCHEMBL22860321 | 0.76 | CDK2 (0.68) | CDK2CDK1CDK9CCNE1CCNE2 | |
| SCHEMBL1783311 | 0.74 | JAK3 (0.48) | CDK2CDK9CCNE1CDK4CCND1 | |
| SCHEMBL5634313 | 0.73 | CYP1A2 (0.68) | CDK2CDK1CDK9CCNE1PLK1 | |
| SCHEMBL1781892 | 0.71 | CDK4 (0.61) | CDK2CDK4CCNA2CCND1CDK6 | |
| SCHEMBL1782186 | 0.70 | PRKDC (0.57) | CDK2CDK1CDK9CCNE1CCNE2 | |
| SCHEMBL1781001 | 0.70 | PRKDC (0.73) | CDK2CCNA2PRKDC | |
| SCHEMBL1780374 | 0.70 | TTK (0.79) | CDK2PLK1CDK4CCNA2CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103298814-A | 2-Anilinopurin-8-ones as TTK/MPS1 inhibitors for the treatment of proliferative diseases | ASTRAZENECA AB | 2013-09-11 | — | — | CN | disclosed |
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | disclosed |
| EP-2212326-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009024824-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BUB1, BUB1B, TTBK1 | CDK2 134/4885CDK1 31/4885CDK9 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.